Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (167)	12/9/1999 1:01:00 PM
From: Jim Oravetz	of 370

Vion Pharma Administers Tapet To First Phase I Patients NEW HAVEN, Conn. (Dow Jones)--Vion Pharmaceuticals Inc. (VION) said VNP20009, its first-generation Tapet bacterial vector, has been administered to the first patients enrolled into its Phase I intratumoral trial. Tapet are highly attenuated bacteria that have shown preferential replication in tumors compared to normal tissues in preclinical studies. Preferential replication lets the bacteria produce and deliver anticancer therapeutic products to tumors while minimizing toxicity to normal tissues. In a press release Wednesday, the biopharmaceutical company said the Phase I study, which is being conducted at the Cleveland Clinic Foundation, is designed to evaluate the safety, efficacy and optimum dose of an intratumoral administration for patients with either cutaneous or subcutaneous solid tumors. The company said the trial may involve up to 20 to 30 patients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next